Vaccinex (OTC:VCNX) Stock, Quote.Headers.trade-ideas

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

10 New Updates On COVID And Vaccines From CDC That You Need To Know

News

Movers

VCNX

Vaccinex, Inc. (NASDAQ: VCNX) shares are trading lower after the company announced it received a delisting notification from Nasdaq. Here&#39;s what you need to know.

Vaccinex Faces Nasdaq Delisting: What&#39;s Going On With The Stock?

Energy stocks

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

DBGI

PRTG

QUBT

TNXP

TNYA

Crude Oil Down Over 1%; US Industrial Production Declines In November

retail-sales-ai

Intraday Update

OPTX

Dow Dips Over 200 Points; US Retail Sales Top Estimates

Vaccinex Inc

Health Care

Press Releases

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Financing

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

General

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Comments

Vaccinex

Vaccinex (OTC:VCNX) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell